Skip to main content
. Author manuscript; available in PMC: 2017 Dec 18.
Published in final edited form as: Cancer Chemother Pharmacol. 2017 Aug 2;80(3):631–643. doi: 10.1007/s00280-017-3409-3

Figure 1.

Figure 1

PAR level in PBMCs from patients treated with gemcitabine plus veliparib. Blood samples were drawn at the indicated times. PBMCs were isolated and processed for PAR ELISA. Clinical events (PR, partial response; SD, stable disease; DLT, dose limiting toxicity) are listed behind patient identifier.